[go: up one dir, main page]

WO2011111971A3 - (ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법 - Google Patents

(ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법 Download PDF

Info

Publication number
WO2011111971A3
WO2011111971A3 PCT/KR2011/001579 KR2011001579W WO2011111971A3 WO 2011111971 A3 WO2011111971 A3 WO 2011111971A3 KR 2011001579 W KR2011001579 W KR 2011001579W WO 2011111971 A3 WO2011111971 A3 WO 2011111971A3
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
oxazolidin
triazin
dihydro
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/001579
Other languages
English (en)
French (fr)
Other versions
WO2011111971A2 (ko
Inventor
조영락
백성윤
채상은
이홍범
박태교
우성호
김용주
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligachem Biosciences Inc
Original Assignee
Legochem Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legochem Biosciences Inc filed Critical Legochem Biosciences Inc
Priority to CN201180013805.4A priority Critical patent/CN102803256B/zh
Priority to US13/583,492 priority patent/US8703939B2/en
Publication of WO2011111971A2 publication Critical patent/WO2011111971A2/ko
Publication of WO2011111971A3 publication Critical patent/WO2011111971A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 사이클릭 아미드라존 기를 가지는 옥사졸리디논계 항생제 화합물인 (R)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1H)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체를 제조하는 방법 및 그 중간체에 관한 것으로, 출발물질로 3,4-다이플루오로-4-니트로벤젠을 사용한다. 본 발명의 제조방법에 따르면 종래 방법에 비해 간단한 방법으로 옥사졸리디논계 항생제로 유용한 화합물인 (R)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1H)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체를 고순도 및 고수율로 제조할 수 있다.
PCT/KR2011/001579 2010-03-08 2011-03-08 (ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법 Ceased WO2011111971A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201180013805.4A CN102803256B (zh) 2010-03-08 2011-03-08 (r)-3-(3-氟-4-(1-甲基-5,6-二氢-1,2,4-三嗪-4(1h)-基)苯基)-5-(取代甲基)恶唑烷-2-酮衍生物的制备方法
US13/583,492 US8703939B2 (en) 2010-03-08 2011-03-08 Method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0020525 2010-03-08
KR1020100020525A KR101128029B1 (ko) 2010-03-08 2010-03-08 (ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법

Publications (2)

Publication Number Publication Date
WO2011111971A2 WO2011111971A2 (ko) 2011-09-15
WO2011111971A3 true WO2011111971A3 (ko) 2012-01-12

Family

ID=44563981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/001579 Ceased WO2011111971A2 (ko) 2010-03-08 2011-03-08 (ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법

Country Status (4)

Country Link
US (1) US8703939B2 (ko)
KR (1) KR101128029B1 (ko)
CN (1) CN102803256B (ko)
WO (1) WO2011111971A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115702900B (zh) * 2021-08-09 2024-02-09 上海纳为生物技术有限公司 一种rmx2001制剂组合物
KR102608785B1 (ko) 2021-12-27 2023-12-04 가톨릭대학교 산학협력단 옥사졸리딘-2-온 유도체 및 이의 제조 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035648A1 (en) * 2001-10-25 2003-05-01 Astrazeneca Ab Aryl substituted oxazolidinones with antibacterial activity
WO2004048350A2 (en) * 2002-11-28 2004-06-10 Astrazeneca Ab Oxazolidinones as antibacterial agents
WO2004056819A1 (en) * 2002-12-19 2004-07-08 Astrazeneca Ab Oxazolidinone derivatives as antibacterial agents
EP2072513A1 (en) * 2007-12-17 2009-06-24 Ferrer Internacional, S.A. A cyano piperidinyl-phenil-oxazolidinone and use thereof
EP2072514A1 (en) * 2007-12-17 2009-06-24 Ferrer Internacional, S.A. 1(2)H-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents
WO2010036000A2 (en) * 2008-09-24 2010-04-01 Legochem Bioscience Ltd. Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0227704D0 (en) * 2002-11-28 2003-01-08 Astrazeneca Ab Chemical compounds
EP2141162A1 (en) 2008-07-01 2010-01-06 Ferrer Internacional, S.A. 3-(n-heterocyclyl)-pyrrolidinyl-phenyl-oxazolidinones as antibacterial agents
EP2141161A1 (en) 2008-07-01 2010-01-06 Ferrer Internacional, S.A. 3-cyanopyrrolidinyl-phenyl-oxazolidinones as antibacterial agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035648A1 (en) * 2001-10-25 2003-05-01 Astrazeneca Ab Aryl substituted oxazolidinones with antibacterial activity
WO2004048350A2 (en) * 2002-11-28 2004-06-10 Astrazeneca Ab Oxazolidinones as antibacterial agents
WO2004056819A1 (en) * 2002-12-19 2004-07-08 Astrazeneca Ab Oxazolidinone derivatives as antibacterial agents
EP2072513A1 (en) * 2007-12-17 2009-06-24 Ferrer Internacional, S.A. A cyano piperidinyl-phenil-oxazolidinone and use thereof
EP2072514A1 (en) * 2007-12-17 2009-06-24 Ferrer Internacional, S.A. 1(2)H-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents
WO2010036000A2 (en) * 2008-09-24 2010-04-01 Legochem Bioscience Ltd. Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
KR20110101499A (ko) 2011-09-16
CN102803256A (zh) 2012-11-28
WO2011111971A2 (ko) 2011-09-15
US20130005967A1 (en) 2013-01-03
KR101128029B1 (ko) 2012-03-29
US8703939B2 (en) 2014-04-22
CN102803256B (zh) 2015-03-18

Similar Documents

Publication Publication Date Title
IL223002A0 (en) Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide
WO2010042887A3 (en) Methods for preparing oxazolidinones and compositions containing them
WO2013186792A3 (en) Process for preparation of azilsartan medoxomil and its salts
WO2011141933A3 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
WO2012107814A8 (en) An improved process for the preparation of azilsartan medoxomil
MY161482A (en) Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnapthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
WO2009053854A3 (en) Polymorphs of dasatinib and process for preparation thereof
MY150980A (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives
WO2009006590A3 (en) Docetaxel process and polymorphs
WO2011048604A3 (en) Processes for the preparation of darunavir and the amorphous form thereof
WO2010067374A3 (en) Polymorphs of dasatinib
WO2010014566A3 (en) Process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol
EP2613787A4 (en) PROCESSES FOR THE PREPARATION OF 4- {4- [5 (S) - (AMINOMETHYL) -2-OXO-1,3-OXAZOLIDIN-3-YL] PHENYL} MORPHOLIN-3-ONE
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2012046253A3 (en) Process for preparation of n-[2-(7-methoxy-1-naphtityl)ethyl] acetamide and its novel crystalline forms
WO2010084514A3 (en) A process for the preparation of (5s)-(n)-[[3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide
WO2011024192A3 (en) Novel polymorphs of raltegravir
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
IL219013A0 (en) Novel solid form of 4-[[(6-chloropyridin-3-yl)methyl(2,2-difluoroethy)amino]furan-2(5h)-one
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
WO2011111971A3 (ko) (ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법
WO2009062659A3 (en) Polymorphs of enantiopure erdosteine
WO2009116081A3 (en) An improved process for the preparation of aprepitant
WO2013088384A3 (en) Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
WO2010140132A8 (en) Process for the preparation of crystalline aprepitant having form i content

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180013805.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11753576

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2091/MUMNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 13583492

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11753576

Country of ref document: EP

Kind code of ref document: A2